Palo Alto Investors »

Sagimet Biosciences Inc-a shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Sagimet Biosciences Inc-a (SGMT) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Sagimet Biosciences Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Sagimet Biosciences Inc-a held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sagimet Biosciences Inc-a by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.9M 250k 7.73

More positions owned by Palo Alto Investors

Ptc Therapeutics I (PTCT)
ACADIA Pharmaceuticals (ACAD)
Insmed Com Par $.01 (INSM)
Mirum Pharmaceuticals Note 4.000% 5/0 (Principal)
Anaptysbio Inc Common (ANAB)
BioMarin Pharmaceutical (BMRN)
Dyne Therapeutics (DYN)
United Therapeutics Corporation (UTHR)
Disc Medicine (IRON)
Biogen Idec (BIIB)
Iovance Biotherapeutics (IOVA)
Ultragenyx Pharmaceutical (RARE)
Novocure Ord Shs (NVCR)
Syndax Pharmaceuticals (SNDX)
Annexon (ANNX)

View all positions for Palo Alto Investors

Top funds holding Sagimet Biosciences Inc-a

BlackRock
Balyasny Asset Management
Woodline Partners
Silverarc Capital Management
Vanguard Capital Management
BVF
Caligan Partners
Affinity Asset Advisors
Federated Investors
Dr. Jeffrey R. Jay, M.D.
Saturn V Capital Management
Geode Capital Management
Blue Owl Capital Holdings
Baker Bros. Advisors
Millennium Management

View all funds holding Sagimet Biosciences Inc-a